Royalty revenue 1.16B KRW (up from 0.38B KRW) due to strong Intas Pegfilgrastim sales.
Completed cancellation of 120,000 treasury shares (Nov 2025) and acquisition of 140,404 shares (Jul 2025). Ongoing shareholder return.
Artificial blood SBX completed preclinical tox at Charles River, US patent granted (US 12,295,991, May 2025). CloudPEG technology filed in US and Korea.
Debt ratio 113.3% (previous year-end 110.2%), convertible bonds 5B KRW outstanding. Short-term loan to CEO 1.54B KRW maintained.